Flexible graphene-based neurotechnology for high-precision deep brain mapping and neuromodulation in Parkinsonian rats.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40133322.
- Also identified by DOI 10.1038/s41467-025-58156-z and PMC identifier 11937542.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Deep brain stimulation (DBS) is a neuroelectronic therapy for the treatment of a broad range of neurological disorders, including Parkinson's disease. Current DBS technologies face important limitations, such as large electrode size, invasiveness, and lack of adaptive therapy based on biomarker monitoring. In this study, we investigate the potential benefits of using nanoporous reduced graphene oxide (rGO) technology in DBS, by implanting a flexible high-density array of rGO microelectrodes (25 µm diameter) in the subthalamic nucleus (STN) of healthy and hemi-parkinsonian rats. We demonstrate that these microelectrodes record action potentials with a high signal-to-noise ratio, allowing the precise localization of the STN and the tracking of multiunit-based Parkinsonian biomarkers. The bidirectional capability to deliver high-density focal stimulation and to record high-fidelity signals unlocks the visualization of local neuromodulation of the multiunit biomarker. These findings demonstrate the potential of bidirectional high-resolution neural interfaces to investigate closed-loop DBS in preclinical models.
Medical subject headings
- Graphite
- Deep Brain Stimulation
- Parkinson Disease
- Brain Mapping